iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
We know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment
 
  Download the PDF here
 
Reported by Jules Levin
NATAP
www.natap.org
 
Associate Professor Jason Grebely
National Drug & Alcohol Research Centre, Sydney, Australia, 17th May 2018

AASDL1

Reported by Jules Levin
NATAP
www.natap.org
 
Associate Professor Jason Grebely
National Drug & Alcohol Research Centre, Sydney, Australia, 17th May 2018

AASDL2

AASDL3

AASDL4

EASL: The PREVAIL Study: Intensive Models of HCV Care for People Who Inject Drugs - (04/26/17)
 
EASL: Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study - (04/24/17)
 
C-EDGE CO-STAR: Interim Results From the 3-year Follow-up Trial on Risk Factors and Rate of Reinfection in Patients on Opiate Agonist Therapy Previously Treated With Elbasvir/Grazoprevir for 12 Weeks

AASDL5

AASDL6

AASDL7

AASDL8

AASDL9

AASDL10

AASDL11

AASDL12

AASDL13

AASDL14

AASDL15

AASDL16

AASDL17

AASDL18

AASDL19

AASDL20

AASDL21

AASDL22

AASDL23

AASDL24

AASDL25

AASDL26

AASDL27

AASDL28

AASDL29

AASDL30

AASDL31

AASDL32

AASDL33

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org